Immucell (ICCC) Other Non-Current Liabilities (2017 - 2023)
Immucell's (ICCC) quarterly Other Non-Current Liabilities came in at $9.3 million in Q2 2023, down 3.33% quarter-over-quarter from $9.6 million in Q1 2023.
Powered by 
Analysis
Immucell (ICCC) Other Non-Current Liabilities (2017 - 2023) Analysis & Trends
Immucell (ICCC) has reported Other Non-Current Liabilities for 3 consecutive years, with $9.3 million the latest figure, recorded in Q2 2023.
- For the quarter ending Q2 2023, Other Non-Current Liabilities changed N/A year-over-year to $9.3 million; the trailing twelve-month figure through Jun 2023 stood at $9.3 million (changed N/A YoY), and the FY2019 full-year result was $58526.0, changed N/A from the prior year.
- Other Non-Current Liabilities declined to $9.3 million in Q2 2023 per ICCC's latest filing, from $9.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $9.6 million in Q1 2023 and bottomed at $57216.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 9.26 Mn |
| Mar 31, 2023 | 9.58 Mn |
| Dec 31, 2019 | 58,526.00 |
| Sep 30, 2019 | 86,973.00 |
| Jun 30, 2019 | 57,216.00 |
| Dec 31, 2017 | 996.00 |